More Details on This News

Caplin Point Laboratories Limited, through its subsidiaries Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL), has acquired ten approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic product manufacturing company. The addressable market for these products was valued at $473.2 million for the 12-month period ending August 2025.

Mr. C.C. Paarthipan, Chairman of Caplin Point, stated that the U.S. market is a key growth driver, and this acquisition significantly accelerates their strategy by expanding and strengthening their portfolio in the region. The acquired portfolio includes select oncology injectables that will be commercialized from their new dedicated oncology facility in Kakkalur. The company also intends to extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil.

Caplin Steriles Limited (CSL), a subsidiary, is a fast-growing sterile product manufacturer approved by regulatory agencies like US FDA, EU-GMP, ANVISA, and INVIMA. CSL has independently filed 53 ANDAs in the USA with 49 approvals (including acquired ones) and is developing a portfolio of over 55 injectable and ophthalmic products for future filings. Caplin One Labs Limited (COL) is operating its oncology unit and has acquired 5 of the 10 ANDAs under this acquisition.

Caplin Point Laboratories Limited is known for its unique business model focused on emerging markets in Latin America and Africa, with consistent high-quality growth in cash flows, profitability, and revenues over the last 15 years. The company has been recognized multiple times on Forbes “Asia’s 200 Best Under a Billion” list and has received other business excellence awards.